RARB and open-angle glaucoma: Some other drug candidates targeting proteins encoded by POAG-associated loci are also currently under consideration for treating dementia and cardiovascular diseases including acitretin, a retinoid receptor agonist targeting RARB, which has been considered for treatment of AD in ongoing clinical trials.